Agify is a team based between Marseille and Station F (Paris). We operate Medify, an outbound prospecting service built for MedTech companies selling to French healthcare facilities. It's a market with long, multi-stakeholder cycles where intent signals don't appear in any standard intent tool.
Agify was born from a simple observation: generic B2B prospecting agencies understand nothing about hospital buying cycles. They apply SaaS playbooks to a market governed by public procurement, HAS certifications, tenders, and a dozen stakeholders who must align before a single euro is signed.
The result: brilliant MedTech companies with clinically superior products spend years struggling to break into the French market. Not for lack of relevance, but for lack of a prospecting method that respects the codes of the sector.
"You don't sell a CRM to a hospital. You trigger an investment project that will cross six people, three committees and two budget cycles. The prospecting that works is the one that already speaks the language of that reality."
We built Medify as the technical answer to this problem: an outbound service that leverages French public data (HAS, IQSS, IFAQ, PMSI, SAE) to detect who is investing, on which topics, and at which window.
AI-powered B2B commercial automation studio. Builds and operates verticalized outbound products.
The dedicated service for MedTech companies selling to French hospitals. Integrates regulatory signals and public healthcare data sources.
Selling to hospitals is one of the most complex B2B sales in the French market. It combines a long cycle (3 to 24 months), multiple uncoordinated decision makers (clinician + biomedical + procurement + management), a strict regulatory framework, and rigid budget windows.
Our mission: turn this complexity into a predictable commercial pipeline for MedTech companies. Not by promising miracles, but by applying a rigorous, documented method that relies on the intent signals the sector already emits publicly.
We only work with MedTech companies whose product, CE marking and sales team are ready to honour the qualified meetings we generate. That's our entry filter, and it's what allows us to keep our performance commitments.
Our method flows from these beliefs. If you disagree with them, Medify is probably not the right service for you, and that's perfectly fine.
Classic intent tools (6sense, Bombora) see nothing of the French hospital market. The real signals are in HAS reports, IQSS/IFAQ indicators and ARS authorizations. Free, public, infinitely more precise.
Contacting only the clinician who will use the device is trap number 1. We systematically contact user + buyer in parallel, with two calibrated value angles. Otherwise, the deal dies internally.
A healthcare manager receives 12 commercial messages per week. What makes the difference is a verifiable fact about their facility in the first line. A SAE figure, an IFAQ score, an ongoing certification.
3,000 French hospitals, that's it. You cannot compensate for poor targeting with volume. Better 120 finely scored accounts than 800 approximate contacts. The quality of the list determines everything.
We operate from Marseille and Station F in Paris, where Agify is currently incubated. This dual presence gives us a southern anchor and direct access to the Parisian MedTech ecosystem and university hospitals.
Our historical and operational base. This is where our dev team is based: the one that builds the scoring platform, open data ingestion pipelines and internal sprint orchestration tools. Southern and Mediterranean anchor, close to AP-HM, CHUs in the PACA-Occitanie region and a fast-growing south-European MedTech ecosystem.
Agify is currently incubated at Station F, the world's largest startup campus. This office puts us in direct contact with Parisian MedTech companies, AP-HP, major Ile-de-France hospital groups and the French health startup community.
The Medify diagnostic is a 45-minute no-commitment call. At the end, you leave with your hospital segment quantified, your priority IQSS/IFAQ indicators, your prospectable volume and a realistic meeting estimate.